SAN DIEGO--(BUSINESS WIRE)--Function Oncology, a company transforming the future of targeted cancer treatment with a CRISPR-powered precision medicine platform, today announced an upcoming presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting. The presentation will feature data from an acute myeloid leukemia (AML) cohort that demonstrate the power of Function Oncology’s CRISPR-based personalized functional genomics platform to profile and understand cancer in unprecedented and patient-specific detail.
“These data underscore the powerful potential of our functional genomics platform to produce tailored treatment strategies,” said Srihari Sampath, M.D., Ph.D., MPhil, co-founder and chief scientific officer. “In this study, our platform achieved very high sensitivity and specificity to identify gene dependencies driving individual patient responses, as well as high predictive value for observed clinical outcomes. For the first time, we are able to efficiently move beyond traditional gene sequencing to directly measuring gene function in order to define optimal therapeutic strategies for cancer patients.”
Details of the presentation are as follows:
Title: A comprehensive CRISPR-enabled functional genomics profiling platform in Acute Myeloid Leukemia (AML): pilot study and validation of Fx Heme
Format: Poster presentation
Abstract Number: 1062
Session Title: Session PO.CL09.03 - Precision Molecular Subtyping and Therapeutic Development
Date and Time: Sunday, April 16, 2023, 1:30 PM - 5:00 PM ET
About Function Oncology
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring gene function, Function Oncology aims to identify optimal therapeutic opportunities for patients and advance the next generation of targeted cancer therapies. To learn more, please visit functiononcology.com and follow us on LinkedIn.
